18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. / Binderup, Tina; Knigge, Ulrich; Loft, Annika; Federspiel, Birgitte; Kjaer, Andreas; Binderup, Tina; Knigge, Ulrich; Jakobsen, Annika Loft; Federspiel, Birgitte Hartnack; Kjær, Andreas.

In: Clinical Cancer Research, Vol. 16, No. 3, 01.02.2010, p. 978-85.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Binderup, T, Knigge, U, Loft, A, Federspiel, B, Kjaer, A, Binderup, T, Knigge, U, Jakobsen, AL, Federspiel, BH & Kjær, A 2010, '18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors', Clinical Cancer Research, vol. 16, no. 3, pp. 978-85. https://doi.org/10.1158/1078-0432.CCR-09-1759, https://doi.org/10.1158/1078-0432.CCR-09-1759

APA

Binderup, T., Knigge, U., Loft, A., Federspiel, B., Kjaer, A., Binderup, T., ... Kjær, A. (2010). 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clinical Cancer Research, 16(3), 978-85. https://doi.org/10.1158/1078-0432.CCR-09-1759, https://doi.org/10.1158/1078-0432.CCR-09-1759

Vancouver

Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A, Binderup T et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clinical Cancer Research. 2010 Feb 1;16(3):978-85. https://doi.org/10.1158/1078-0432.CCR-09-1759, https://doi.org/10.1158/1078-0432.CCR-09-1759

Author

Binderup, Tina ; Knigge, Ulrich ; Loft, Annika ; Federspiel, Birgitte ; Kjaer, Andreas ; Binderup, Tina ; Knigge, Ulrich ; Jakobsen, Annika Loft ; Federspiel, Birgitte Hartnack ; Kjær, Andreas. / 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 3. pp. 978-85.

Bibtex

@article{b07e71605fff11df928f000ea68e967b,
title = "18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors",
abstract = "PURPOSE: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently not used on a routine basis for imaging of neuroendocrine (NE) tumors. The aim of this study was to investigate the prognostic value of FDG-PET in patients with NE tumors. EXPERIMENTAL DESIGN: Ninety-eight prospectively enrolled patients with NE tumors underwent FDG-PET imaging. FDG uptake was quantified by maximal standardized uptake value (SUVmax). The prognostic value of FDG uptake, proliferation index, chromogranin A, and liver metastases were assessed. RESULTS: During the 1-year follow-up, 14 patients died. The diagnostic sensitivity of FDG-PET was 58{\%} (n = 57) and a positive FDG-PET result was associated with a significantly higher risk of death with a hazard ratio (HR) of 10.3 [95{\%} confidence interval (CI), 1.3-78.9]. Thirteen of the 57 (23{\%}) FDG-PET-positive patients died compared with 1 of 41 (2{\%}) FDG-PET-negative patients. By univariate analysis, a SUVmax of >9 and a high Ki67 index were significant predictors of overall survival with a HR of 8.8 (95{\%} CI, 2.7-28.7) and a HR of 2.6 (95{\%} CI, 1.3-5.1), respectively. In a multivariate analysis including a SUVmax of >3, Ki67, and chromogranin A, SUVmax of >3 was the only predictor of progression-free survival (HR, 8.4; P < 0.001). CONCLUSIONS: This study shows a strong prognostic value of FDG-PET for NE tumors, which exceeds the prognostic value of traditional markers such as Ki67, chromogranin A, and liver metastases. FDG-PET may obtain an important role for NE tumors.",
author = "Tina Binderup and Ulrich Knigge and Annika Loft and Birgitte Federspiel and Andreas Kjaer and Tina Binderup and Ulrich Knigge and Jakobsen, {Annika Loft} and Federspiel, {Birgitte Hartnack} and Andreas Kj{\ae}r",
note = "Keywords: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Predictive Value of Tests; Prognosis",
year = "2010",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1759",
language = "English",
volume = "16",
pages = "978--85",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research (A A C R)",
number = "3",

}

RIS

TY - JOUR

T1 - 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

AU - Binderup, Tina

AU - Knigge, Ulrich

AU - Loft, Annika

AU - Federspiel, Birgitte

AU - Kjaer, Andreas

AU - Binderup, Tina

AU - Knigge, Ulrich

AU - Jakobsen, Annika Loft

AU - Federspiel, Birgitte Hartnack

AU - Kjær, Andreas

N1 - Keywords: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Predictive Value of Tests; Prognosis

PY - 2010/2/1

Y1 - 2010/2/1

N2 - PURPOSE: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently not used on a routine basis for imaging of neuroendocrine (NE) tumors. The aim of this study was to investigate the prognostic value of FDG-PET in patients with NE tumors. EXPERIMENTAL DESIGN: Ninety-eight prospectively enrolled patients with NE tumors underwent FDG-PET imaging. FDG uptake was quantified by maximal standardized uptake value (SUVmax). The prognostic value of FDG uptake, proliferation index, chromogranin A, and liver metastases were assessed. RESULTS: During the 1-year follow-up, 14 patients died. The diagnostic sensitivity of FDG-PET was 58% (n = 57) and a positive FDG-PET result was associated with a significantly higher risk of death with a hazard ratio (HR) of 10.3 [95% confidence interval (CI), 1.3-78.9]. Thirteen of the 57 (23%) FDG-PET-positive patients died compared with 1 of 41 (2%) FDG-PET-negative patients. By univariate analysis, a SUVmax of >9 and a high Ki67 index were significant predictors of overall survival with a HR of 8.8 (95% CI, 2.7-28.7) and a HR of 2.6 (95% CI, 1.3-5.1), respectively. In a multivariate analysis including a SUVmax of >3, Ki67, and chromogranin A, SUVmax of >3 was the only predictor of progression-free survival (HR, 8.4; P < 0.001). CONCLUSIONS: This study shows a strong prognostic value of FDG-PET for NE tumors, which exceeds the prognostic value of traditional markers such as Ki67, chromogranin A, and liver metastases. FDG-PET may obtain an important role for NE tumors.

AB - PURPOSE: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently not used on a routine basis for imaging of neuroendocrine (NE) tumors. The aim of this study was to investigate the prognostic value of FDG-PET in patients with NE tumors. EXPERIMENTAL DESIGN: Ninety-eight prospectively enrolled patients with NE tumors underwent FDG-PET imaging. FDG uptake was quantified by maximal standardized uptake value (SUVmax). The prognostic value of FDG uptake, proliferation index, chromogranin A, and liver metastases were assessed. RESULTS: During the 1-year follow-up, 14 patients died. The diagnostic sensitivity of FDG-PET was 58% (n = 57) and a positive FDG-PET result was associated with a significantly higher risk of death with a hazard ratio (HR) of 10.3 [95% confidence interval (CI), 1.3-78.9]. Thirteen of the 57 (23%) FDG-PET-positive patients died compared with 1 of 41 (2%) FDG-PET-negative patients. By univariate analysis, a SUVmax of >9 and a high Ki67 index were significant predictors of overall survival with a HR of 8.8 (95% CI, 2.7-28.7) and a HR of 2.6 (95% CI, 1.3-5.1), respectively. In a multivariate analysis including a SUVmax of >3, Ki67, and chromogranin A, SUVmax of >3 was the only predictor of progression-free survival (HR, 8.4; P < 0.001). CONCLUSIONS: This study shows a strong prognostic value of FDG-PET for NE tumors, which exceeds the prognostic value of traditional markers such as Ki67, chromogranin A, and liver metastases. FDG-PET may obtain an important role for NE tumors.

U2 - 10.1158/1078-0432.CCR-09-1759

DO - 10.1158/1078-0432.CCR-09-1759

M3 - Journal article

C2 - 20103666

VL - 16

SP - 978

EP - 985

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -

ID: 19751819